



# Prior Authorization Request Administrative Information

## Member information

Last name  First name  MI

Member ID  Date of birth

Sex assigned at birth  Female  Male  "X" or Intersex

Current gender  Female  Male  Transgender male  Transgender female  Other

Place of residence  Home  Nursing facility  Other

Race  Ethnicity

Preferred spoken language  Preferred written language

MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).

## Plan contact information

Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to the Plan's contact information below.

<b>MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, and Children's Medical Security Plan</b>
<input type="checkbox"/> <b>MassHealth Drug Utilization Review Program</b> Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318
<b>MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)</b>
<input type="checkbox"/> <b>Fallon Health</b> Online Prior Authorization: <a href="http://go.covermymeds.com/OptumRx">go.covermymeds.com/OptumRx</a> Online Prior Authorization: <a href="http://providerportal.surescripts.net/ProviderPortal/optum">providerportal.surescripts.net/ProviderPortal/optum</a> Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033
<input type="checkbox"/> <b>Health New England</b> Online Prior Authorization: <a href="http://go.covermymeds.com/OptumRx">go.covermymeds.com/OptumRx</a> Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545
<input type="checkbox"/> <b>Mass General Brigham Health Plan</b> Online Prior Authorization (Pharmacy Benefit Reviews): <a href="http://go.covermymeds.com/OptumRx">go.covermymeds.com/OptumRx</a> Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555 Online Prior Authorization (Medical Specialty Reviews): <a href="http://provider.massgeneralbrighamhealthplan.org">provider.massgeneralbrighamhealthplan.org</a> Medical Specialty Reviews: Fax: (888) 656-6671 - Tel: (833) 895-2611
<input type="checkbox"/> <b>Tufts Health Plan</b> Online Prior Authorization: <a href="http://point32health.promptpa.com">point32health.promptpa.com</a> Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985
<input type="checkbox"/> <b>WellSense Health Plan</b> Online Prior Authorization: <a href="http://wellsense.org/providers/ma/pharmacy/prior-authorizations">wellsense.org/providers/ma/pharmacy/prior-authorizations</a> Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822

# Antidepressant Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about antidepressants and the **Pediatric Behavioral Health Medication Initiative**, including PA requirements, a complete list of all behavioral health medications, and preferred products, can be found within the MassHealth Drug List at [www.mass.gov/druglist](http://www.mass.gov/druglist). The related PA form is available at: **Pediatric Behavioral Health Medication Initiative PA Request Form**.

## Medication information

### Medication requested

- |   |  |   |
|---|--|---|
| <input type="checkbox"/> amoxapine  | <input type="checkbox"/> desvenlafaxine succinate                        | <input type="checkbox"/> protriptyline  |
| <input type="checkbox"/> Auvelity (dextromethorphan/<br>bupropion)            | <input type="checkbox"/> extended-release 100 mg tablet<br>> 4 units/day | <input type="checkbox"/> Raldesy (trazodone solution)                         |
| <input type="checkbox"/> bupropion XL > 1 unit/day                            | <input type="checkbox"/> Drizalma (duloxetine sprinkle                   | <input type="checkbox"/> sertraline capsule                                   |
| <input type="checkbox"/> bupropion hydrochloride                              | <input type="checkbox"/> capsule)  | <input type="checkbox"/> Spravato (esketamine)                                |
| <input type="checkbox"/> extended-release 450 mg tablet                       | <input type="checkbox"/> duloxetine 40 mg capsule                        | <input type="checkbox"/> trazodone 300 mg tablet                              |
| <input type="checkbox"/> citalopram capsule                                   | <input type="checkbox"/> Emsam (selegiline)                              | <input type="checkbox"/> trimipramine   |
| <input type="checkbox"/> clomipramine   | <input type="checkbox"/> Fetzima (levomilnacipran)                       | <input type="checkbox"/> Trintellix (vortioxetine)                            |
| <input type="checkbox"/> desipramine  | <input type="checkbox"/> fluoxetine 60 mg tablet                         | <input type="checkbox"/> venlafaxine besylate extended-<br>release tablet     |
| <input type="checkbox"/> desvenlafaxine extended-<br>release                  | <input type="checkbox"/> fluoxetine 90 mg delayed-<br>release capsule    | <input type="checkbox"/> venlafaxine hydrochloride<br>extended-release tablet |
| <input type="checkbox"/> desvenlafaxine succinate                             | <input type="checkbox"/> fluvoxamine extended-release                    | <input type="checkbox"/> vilazodone   |
| <input type="checkbox"/> extended-release 25 mg, 50 mg<br>tablet > 1 unit/day | <input type="checkbox"/> imipramine pamoate tablet                       | <input type="checkbox"/> Zurzuvae (zuranolone)                                |
|   | <input type="checkbox"/> Ketalar (ketamine injection) <sup>MB</sup>      | <input type="checkbox"/> Other* <input type="text"/>                          |
|   | <input type="checkbox"/> Marplan (isocarboxazid)                         |   |
|   | <input type="checkbox"/> mirtazapine orally                              |   |
|   | <input type="checkbox"/> disintegrating tablet                           |   |
|   | <input type="checkbox"/> olanzapine/fluoxetine                           |   |
|   | <input type="checkbox"/> paroxetine controlled-release                   |   |

\* If request is for a non-preferred brand name or generic product, please attach supporting documentation (e.g., copies of medical records and/or office notes regarding adverse reaction or inadequate response to the preferred product).

<sup>MB</sup> This drug is available through the health care professional who administers the drug or in an outpatient or inpatient hospital setting. MassHealth does not pay for this drug to be dispensed through the retail pharmacy. If listed, PA does not apply through the acute hospital inpatient setting, unless on the APAD/APEC carve-out drug list, or in the emergency, trauma, or urgent acute hospital outpatient settings. Please refer to 130 CMR 433.408 for PA requirements for other health care professionals. Notwithstanding the above, this drug may be an exception to the unified pharmacy policy; please refer to respective MassHealth Accountable Care Partnership Plans (ACPPs) and Managed Care Organizations (MCOs) for PA status and criteria, if applicable.

### Dose, frequency, and duration of medication requested

Please indicate billing preference.  Pharmacy  Prescriber in-office  Hospital outpatient

If applicable, please also complete section for professionally administered medications at end of form.

Requests for Spravato for *treatment resistant depression*, please select one of the following dosing regimens:

- |                        |   |  |
|------------------------|---|--|
| Weeks 1 to 4:          | <input type="checkbox"/> 56 mg twice weekly | <input type="checkbox"/> 84 mg twice weekly          |
| Weeks 5 to 8:          | <input type="checkbox"/> 56 mg once weekly  | <input type="checkbox"/> 84 mg once weekly           |
| Weeks 9 to 52:         | <input type="checkbox"/> 56 mg once weekly  | <input type="checkbox"/> 56 mg once every other week |
|                        | <input type="checkbox"/> 84 mg once weekly  | <input type="checkbox"/> 84 mg once every other week |
| Greater than 52 weeks: | <input type="checkbox"/> 56 mg once weekly  | <input type="checkbox"/> 56 mg once every other week |
|                        | <input type="checkbox"/> 84 mg once weekly  | <input type="checkbox"/> 84 mg once every other week |

Other.  Week of therapy

Please explain requested dosing.

Requests for Spravato for *Major depressive disorder (MDD) with acute suicidal ideation or behavior*, please select dosing regimen.

84 mg twice weekly for four weeks

Other

Please explain requested dosing.

**Indication** (Check all that apply or include ICD-10 code, if applicable.)

- |  |  |
|--|--|
| <input type="checkbox"/> Major depressive disorder       | <input type="checkbox"/> Panic disorder                        |
| <input type="checkbox"/> Obsessive-compulsive disorder   | <input type="checkbox"/> Postpartum depression                 |
| <input type="checkbox"/> Premenstrual dysphoric disorder | <input type="checkbox"/> Other (describe) <input type="text"/> |

Please list all other psychotropic medications currently prescribed for the member.

Has member been hospitalized for this condition?

Yes. Dates of most recent hospitalization   No

Is the member under the care of psychiatrist?  Yes  No

Name of psychiatrist

Telephone no.  Date of last visit or consult with psychiatrist

Is this member a referral candidate for care coordination?  Yes  No

If yes, MassHealth will offer this member care coordination services. Please describe which additional behavioral health services would be beneficial. *Please inform the member, parent, or legal guardian to expect outreach from a MassHealth representative of care coordination services.*

---

**Section I. Please complete for bupropion hydrochloride extended-release 450 mg tablet, citalopram capsule, desvenlafaxine extended-release, duloxetine 40 mg capsule, fluoxetine 60 mg tablet, fluoxetine 90 mg delayed-release capsule, fluvoxamine extended-release, imipramine pamoate, sertraline capsule, trazodone 300 mg tablet, venlafaxine besylate extended-release tablet, and venlafaxine hydrochloride extended-release tablet requests.**

Please attach medical records documenting an inadequate response (defined as at least four weeks of therapy) or adverse reaction to the respective formulation of the agent requested at an equivalent dose that is available without prior authorization.

**Section II. Please complete for amoxapine, Auvelity, clomipramine, desipramine, Fetzima, Marplan, protriptyline, trimipramine, Trintellix, and vilazodone requests.**

Please describe applicable antidepressant trials and outcomes (attach a letter with additional information regarding trials as applicable).

Drug name  Dates/duration of use  Dose and frequency

Did member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name  Dates/duration of use  Dose and frequency

Did member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

---

**Section III. Please complete for Emsam requests.**

1. Has the member had a trial with one SSRI and one non-SSRI antidepressant?

Yes. Please list the drug name, dose and frequency, dates/duration of trials, and outcomes below.

Drug name  Dose and frequency  Dates/duration of use

Did the member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name  Dose and frequency  Dates/duration of use

Did the member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

No. Please explain why not.

2. Is there a medical necessity for the transdermal formulation?  Yes  No

If yes, please explain.

---

**Section IV. Please complete for Drizalma requests.**

Please document medical necessity for the requested formulation instead of the solid oral formulation.

---

**Section V. Please complete for mirtazapine orally disintegrating tablet requests.**

Is there a medical necessity for the specific dosage formulation?

Yes. Please explain.

No. Has the member tried mirtazapine tablets?

Did the member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

---

**Section VI. Please complete for Raldesy requests.**

1. Does the member have a G-tube/J-tube?  Yes  No

If no, has the member had a trial with crushed trazodone tablets?

Yes. Please list the dose and frequency, dates/duration of trials, and outcomes below.

Dose and frequency

Dates/duration of use

Did the member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

No. Please describe why crushed trazodone tablets is not appropriate for this member.

2. Please describe medical necessity for use of the requested formulation.

3. Has the member had a trial with citalopram solution, escitalopram solution, fluoxetine solution, paroxetine solution, or sertraline solution?

Yes. Please list the drug name, dose and frequency, dates/duration of trials, and outcomes below.

Drug name

Dose and frequency

Dates/duration of use

Did the member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

No. Please describe why citalopram solution, escitalopram solution, fluoxetine solution, paroxetine solution, and sertraline solution are not appropriate for this member.

---

**Section VII. Please complete for olanzapine/fluoxetine requests.**

Please describe the medical necessity for use of the combination product instead of the commercially available separate agents.

---

**Section VIII. Please complete for Ketalar and Spravato requests.**

Requests for Ketalar and Spravato for *treatment resistant depression* and subsequent requests for Spravato for *MDD with acute suicidal ideation or behavior* please complete questions 1 and 2. Initial requests for Spravato for *major depressive disorder (MDD) with acute suicidal ideation or behavior*, please complete questions 3 and 4.

1. Please attach medical records documenting an inadequate response (defined as  $\geq$  four weeks of therapy) or adverse reaction to one SSRI and one non-SSRI antidepressant. If there is a contraindication to SSRI and non-SSRI antidepressants, attach medical records documenting the contraindication.
2. Please attach medical records documenting an inadequate response (defined as  $\geq$  four weeks of therapy) or adverse reaction with one of the following used in combination with an SSRI or other non-SSRI: second-generation antipsychotic, a mood stabilizer such as lithium or lamotrigine, a second antidepressant from a different class, thyroid hormone. If there is a contraindication to all antidepressant augmentation strategies, attach medical records documenting the contraindication.
3. Please attach medical records documenting either current acute suicidal ideation or behavior related to depressive symptoms of MDD, or that the member was stabilized on Spravato during a psychiatric hospitalization.

4. Will the requested agent be used in combination with an oral antidepressant?  Yes  No

---

**Section IX. Please complete for bupropion XL > 1 unit/day, desvenlafaxine succinate extended-release 25 mg, 50 mg tablet > 1 unit/day, or desvenlafaxine succinate extended-release 100 mg tablet > 4 units/day requests.**

Has dose consolidation been attempted?  Yes  No. Please describe medical necessity for quantities above 1 unit/day.

---

**Section X. Please complete for Zurzuvae requests.**

1. Is the member ≤ 12 months postpartum?  Yes. Please document date of delivery.   No

2. Is the member currently pregnant?  Yes  No

3. Has the member had a trial with one of the following: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, mirtazapine, sertraline, venlafaxine?

Yes. Please list the drug name, dose and frequency, dates/duration of trials, and outcomes below.

Drug name  Dose and frequency  Dates/duration of use

Did the member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

No. Please explain why not.

4. Does the member have a requirement for rapid symptom reduction?  Yes  No

5. Requests for 30 mg capsule, does the member have severe hepatic impairment (Child-Pugh Class C) or moderate to severe renal impairment (eGFR < 60 mL/min/1.73m<sup>2</sup>)?

Yes. Please describe.

No

6. For recertification requests, please provide the last day of treatment with the requested agent and the total number of treatments including the current request.

Last day of treatment with requested agent

Total number of treatments including the current request

---

**Section XI. Antidepressant Polypharmacy for members ≥ 18 years of age. Please complete information for medications requested and select the reason for polypharmacy with antidepressants (two or more SSRI, SNRI, or Serotonin Modulator antidepressants for ≥ 60 days within a 90-day period).**

1. Antidepressant name/dose/frequency  Indication

2. Antidepressant name/dose/frequency  Indication

3. Antidepressant name/dose/frequency  Indication

Is member under the care of a psychiatrist?

Yes. Please attach specialist consult details (if the prescriber submitting the request is not a specialist).  No  
For mid-level practitioners (e.g., nurse practitioners, physician assistants), please provide the name and specialty of the collaborating physician, if applicable.

- Member was recently discharged from an inpatient setting on requested medications and is currently stable.
- Member experienced an inadequate response or adverse reaction to two monotherapy trials with antidepressants.

Drug name 1  Dates/Duration of use (if available)

Drug name 2  Dates/Duration of use (if available)

Member is transitioning from one antidepressant to the other.

Other, please explain.

---

**Section XII. Please complete and provide documentation for exceptions to step therapy.**

1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to, the member?  Yes  No

If yes, briefly describe details of contraindication, adverse reaction, or harm.

  

2. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?

Yes  No

If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.

  

3. Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?

Yes  No

If yes, please provide details for the previous trial.

Drug name  Dates/duration of use

Did the member experience any of the following?  Adverse reaction  Inadequate response

Briefly describe details of adverse reaction or inadequate response.

4. Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in, or physical or mental harm to, the member?

Yes. Please provide details.

No

---

**MassHealth Pediatric Behavioral Health Medication Initiative**

Please fill out all the sections below, as applicable, for pediatric members only. You may also use the Pediatric Behavioral Health Medication Initiative PA Request Form if the member is prescribed other behavioral health medications.

---

**Section I. Please complete for all requests for medications subject to the Pediatric Behavioral Health Medication Initiative for members < 18 years of age.**

Please document complete treatment plan listing all requested agents (include all behavioral health agents, corresponding strength, dose, directions of use and indication(s) or ICD-10 code(s), if applicable, for each medication(s)).

1. Medication name	<input type="text"/>	Dose/frequency	<input type="text"/>	Indication	<input type="text"/>
2. Medication name	<input type="text"/>	Dose/frequency	<input type="text"/>	Indication	<input type="text"/>
3. Medication name	<input type="text"/>	Dose/frequency	<input type="text"/>	Indication	<input type="text"/>
4. Medication name	<input type="text"/>	Dose/frequency	<input type="text"/>	Indication	<input type="text"/>
5. Medication name	<input type="text"/>	Dose/frequency	<input type="text"/>	Indication	<input type="text"/>
6. Medication name	<input type="text"/>	Dose/frequency	<input type="text"/>	Indication	<input type="text"/>
7. Other(s)	<input type="text"/>				

Is the member currently in an acute care setting?

- Yes (Inpatient)
  Yes (Community Based Acute treatment)
  Yes (Partial Hospitalization)
  No

For members who are in an acute care setting, please document the outpatient prescriber after discharge.

Prescriber name 
 Contact information

Has the member been hospitalized for a psychiatric condition within the past three months?

- Yes. Please document dates of hospitalization within the past three months. 
  
 No

On the current regimen, is the member considered to be a severe risk of harm to self or others?

- Yes. Please provide details. 
  
 No

For regimens including an antipsychotic, are appropriate safety screenings and monitoring being conducted (e.g., weight, metabolic, movement disorder, cardiovascular, and prolactin-related effects)?

- Yes
  No. Please explain.

Has informed consent from a parent or legal guardian been obtained?\*  Yes  No

Please indicate prescriber specialty:  Psychiatry  Neurology  Other

- Specialist consult details (if the prescriber submitting the request is not a specialist)

Name(s) of the specialist(s) 
 Date(s) of last visit or consult

Contact information

For mid-level practitioners (e.g., nurse practitioners, physician assistants), please provide the name and specialty of the collaborating physician, if applicable.

Please document member custody status.

- Parent/Guardian
  Department of Children and Families (DCF)

Please document member placement status.

- Home with Parent/Guardian
  Foster Care
  Residential Treatment Facility
  Uncertain

Other

Please document agency involvement.

- DCF
  Department of Mental Health (DMH)
  Department of Developmental Services (DDS)
  Department of Youth Services (DYS)

Is the member/family currently receiving appropriate psychotherapeutic and/or community based services for the targeted clinical mental health related concerns (e.g., Applied Behavioral Analysis, Children's Behavioral Health Initiative, school interventions, specialized placement)?

Yes. Please document details of interventions below, if applicable.  No


Psychiatric care provided is coordinated with other psychotherapeutic and community based services.  Yes  No

\* *Sample informed consent form available on the MassHealth PBHMI Information webpage. For additional information, go to <https://www.mass.gov/info-details/pediatric-behavioral-health-medication-initiative-pbhmi-information>.*

Please complete for members who have been on one of the following for the past 12 months with no adjustments (i.e., dose decrease, attempted discontinuation): a polypharmacy regimen, members < six years of age who have been on an applicable behavioral health medication, and members < ten years of age who have been on an antipsychotic.

Have previous efforts to reduce or simplify the regimen in the past 24 months resulted in symptom exacerbation?  Yes  No

The family or caregiver does not support the regimen change at this time due to risk of exacerbation.

Yes  No

Is there another significant barrier for therapy discontinuation?  Yes  No

If yes, please explain. 

--

---

**Section II. Antidepressant Polypharmacy. Complete this section for all members < 18 years of age, if request will result in prescription of two or more antidepressants ≥ 60 days within a 90-day period.**

Please document if monotherapy trials (include drug name, dates/duration of use, and outcome) with antidepressants were tried before prescribing polypharmacy with two or more antidepressants in this member.\*


Please document the treatment plans for medication regimen simplification (e.g., dose consolidation, frequency reduction) or medical necessity for continuation of a complex medication regimen.


Has the member been on an antidepressant polypharmacy regimen for the past 12 months with no adjustments (i.e., dose decrease, attempted discontinuation)?

Yes. Please complete the applicable question in Section I.  No

\**Attach a letter with additional information regarding medication trials as applicable.*

---

**Section III. Antidepressant Request for Members < six years of age.**

Please document any previous medication trial(s). Include the drug name, dates/duration of use, and outcome.\*


Please document clinical rationale for use of an antidepressant for this member < six years of age.


Has the member been on the requested agent for the past 12 months with no adjustments (i.e., dose decrease, attempted discontinuation)?  Yes. Please complete the applicable question in Section I.  No

\**Attach a letter with additional information regarding medication trials as applicable.*

---

**Section IV. Multiple Behavioral Health Medications.**

Complete this section for all members < 18 years of age if request will result in prescriptions of four or more behavioral health medications within a 45-day period if one of the following is included: an antipsychotic, a benzodiazepine, divalproex/valproate, lithium, or a tricyclic antidepressant.

Also complete this section for all members < 18 years of age if request will result in prescriptions of five or more behavioral health medications within a 45-day period. For a complete list of all behavioral health medications, please refer to the MassHealth Pediatric Behavioral Health Medication Initiative.

Please document monotherapy trials (include drug name, dates/duration of use, and outcome) tried before prescribing a polypharmacy regimen for this member.\*


Please document the treatment plans for medication regimen simplification (e.g., dose consolidation, frequency reduction) or medical necessity for continuation of a complex medication regimen.


Has the member been on the requested polypharmacy regimen for the past 12 months with no adjustments (i.e., dose decrease, attempted discontinuation)?  Yes. Please complete the applicable question in Section I.  No

*\*Attach a letter with additional information regarding medication trials as applicable.*

---

**Please continue to next page and complete Prescriber and Provider Information section.**

# Prior Authorization Request Prescriber and Provider Information

## Prescriber information

Last name*	<input type="text"/>	First name*	<input type="text"/>	MI	<input type="text"/>
NPI*	<input type="text"/>	Individual MH Provider ID	<input type="text"/>		
DEA No.	<input type="text"/>	Office Contact Name	<input type="text"/>		
Address	<input type="text"/>	City	<input type="text"/>	State	<input type="text"/>
E-mail address	<input type="text"/>				
Telephone No.*	<input type="text"/>				
Fax No.* (Please provide fax number for PA response notification.)	<input type="text"/>				

\* Required

## Please also complete for professionally administered medications, if applicable.

Start date	<input type="text"/>	End date	<input type="text"/>		
Servicing prescriber/facility name	<input type="text"/>	<input type="checkbox"/>	Same as prescribing provider		
Servicing provider/facility address	<input type="text"/>				
Servicing provider NPI/tax ID No.	<input type="text"/>				
Name of billing provider	<input type="text"/>				
Billing provider NPI No.	<input type="text"/>				
Is this a request for recertification?	<input type="checkbox"/>	Yes	<input type="checkbox"/>	No	
CPT code	<input type="text"/>	No. of visits	<input type="text"/>	J code	<input type="text"/>
				No. of units	<input type="text"/>

## Provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am either the prescribing provider or duly authorized to act on behalf of the provider identified in the Prescriber information section of this form. Any attached statement on letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

### Signature of provider or individual duly authorized to act on behalf of the provider:

Printed legal name and title of signatory above

<input type="text"/>	Date	<input type="text"/>
----------------------	------	----------------------

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)